Ardelyx vs Tarsus Pharmaceuticals
ARDX and TARS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARDX and TARS compare
Tarsus Pharmaceuticals is the larger company, worth 4.4 times as much as Ardelyx ($3.3B against $755M).
Tarsus Pharmaceuticals grew revenue faster over the last twelve months (105% versus 16.8% for Ardelyx).
Tarsus Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −7.7% compared with −12.4% at Ardelyx.
Tarsus Pharmaceuticals scores higher on the StockData Score (11 against 9 for Ardelyx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARDX | TARS |
|---|---|---|
| Size and price | ||
| Market cap | $755M | $3.3B |
| Share price | $3.03 | $74.85 |
| Change, 1 year | −38.9% | 10.9% |
| Change, 5 years | 153% | 169% |
| Beta (5Y) | 0.93 | 0.63 |
| Employees | 489 | 370 |
| StockData Score | ||
| Total score | 9 | 11 (better) |
| Valuation score | 2 (better) | 1 |
| Growth score | 3 | 3 |
| Performance score | 3 | 3 |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.7× (better) | 5.4× |
| P/B | 5.1× (better) | 9.5× |
| P/FCF | – | 58.7× |
| FCF yield | −2.4% | 1.7% (better) |
| Fair value | $7.79 | $75.56 |
| Margin of safety | 61.1% (better) | 0.94% |
| Growth | ||
| Revenue growth (TTM) | 16.8% | 105% (better) |
| Revenue growth, 5Y average | 122% | – |
| Profitability | ||
| Gross margin | 94.4% | – |
| Operating margin | −7.9% (better) | −8.0% |
| Net margin | −12.4% | −7.7% (better) |
| FCF margin | −4.0% | 9.2% (better) |
| Return on equity | −38.6% | −13.7% (better) |
| Financial health | ||
| Debt / equity | – | 0.21 |
| Interest coverage | −1.6× (better) | −5.5× |
| Current ratio | 3.34 (better) | 3.20 |
| Altman Z-score | −0.15 | 7.91 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 71.2% | 110% |
| Held by insiders | 6.9% | 3.1% |
| Insider net buying, 12 months | −$2.4M (better) | −$20.0M |
| Short interest, % of float | 11.9% | 14.3% |
Go deeper
- ARDX stock overview
- ARDX income statement
- ARDX valuation and score
- TARS stock overview
- TARS income statement
- TARS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.